Heart Failure Biomarkers (BIOHF)

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Status

Not yet enrolling

Conditions

Hart Failure

Atrial Fibrillation (AF)

Treatments

Other: Data collection

Study type

Observational

Funder types

Other

Identifiers

NCT06616038

BIOHF

Details and patient eligibility

About

Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE. Study population is composed by patients who were addicted with heart failure diagnosed for the first time or already under treatment (NYHA class II-IV) and reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

Full description

Prospective, observational, single-center study, which involves the enrollment of patients affected by heart failure of first diagnosis or already in therapy, who will be subjected to an analysis of the Albumin/fibrinogen ratio. Subjects will not be subjected to specific visits or services for the study: clinical and anamnestic data will be collected during routine visits.

Enrollment

114 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients ≥ 18 years
Patients with newly diagnosed or already treated heart failure (NYHA class II-IV) with HFrEF and HFpEF with and without atrial fibrillation.
Patients who sign the consent to participate in the study

Exclusion criteria

Patients with infectious/autoimmune diseases, neoplasms, liver failure, renal failure (Cl creatinine < 30 mL/L), structural cardiomyopathies and pericarditis.
Pregnant/breastfeeding women (verified by self-declaration)